ROCKVILLE, Md., May 23, 2017 /PRNewswire/ -- Kalorama information cites two drug candidates that could disrupt the pharmaceutical market in lymphoma and asthma therapeutics market in the next five years, the way the hepatitis and melanoma drug markets have been in the past few years. Kalorama Information, a New York City-based market research firm, said that forecast data were derived from a combination of pipeline analyses, current product treatment guidelines, potential candidate clinical trial results and other factors that may affect the performance of either current or future sales of a particular therapy. Although the firm's report Potential Pipeline Disruptors: New Products That Will Drive the Future Pharmaceutical Market lists six future leaders in drug markets that could change market share, including two candidates in asthma and lymphoma therapeutics that the firm has identified.
"As market researchers, we are on the lookout for products that could upset market share." said Bruce Carlson, Publisher of Kalorama Information. "Assessments of the pharmaceutical market rely on estimates of the current market, with a an adjustment for a normal prediction of the future. In our report, we don't assume a normal future – we are looking for drug candidates that will jump expectations and change established company leadership."
Such developments have happened before. Kalorama defines 'drug pipeline disruptors' as drugs that impact current therapies with significant competition and alter the course of treatment. For the purpose of this study, it may affect current therapies that were also considered disruptor innovations at one time or involves a new innovation that is expected to displace other treatments. As an example, In recent years, several 'disruptors' have hit the market and pushed aside the current standard treatment protocols. Gilead and Bristol-Myers Squibb have produced innovative therapies that can be classified as pipeline disruptors:
- In 2013, Gilead began to rollout its new therapies for HCV, of which the company claimed were superior products to the established market. A bold claim considering it was going up against some of the biggest names in biopharmaceutical participation - mainly Merck and Roche. The market showed favor for Gilead's products, which began to erode sales for Merck and Roche's HCV products. By 2015, Gilead had a solid hold on the market with about 80% market share.
- In December 2014, Bristol-Myers Squibb was granted approval for its PD-1 monoclonal antibody Opdivo (nivolumab). Opdivo was originally granted approval for advanced melanoma; by the end of 2016, lung cancer, renal cell carcinoma, lymphoma, and head & neck cancer were also approved.
The firm cautions that a promising late development project deemed not approvable or other issue could change these forecasts.
In Kalorama Information's Report, the firm identifies nearly 20 potential new drugs that are available in six areas of therapy and highlights the pharmaceutical drug candidate to watch. Among these, Novartis QMF149 in asthma was cited in the report. Novartis is currently studying QVM149 and QMF149 in separate and combined trials including one study that is targeting the superiority of either QVM149 or QMF149. This study is expected to be completed in October 2018 and is being held at 252 locations around the globe. In April 2017, Novartis opened a Phase III trial in Japan for patients with asthma to assess safety.
Bayer's BAY 80-6946 potential lymphoma therapeutic is another drug pipeline prospect predicted to change share in the future pharmaceutical market. Four other potential new drug category leaders from the drug pipeline are detailed in the report.
Kalorama's report is based on its complete and previously published pipeline analysis of the Top 25 pharmaceutical companies. The firm advises that although a thorough analysis and best effort has been made to provide a reliable market forecast, changes can occur which would affect company sales forecasts, market positions/shares, and overall market values. These may include a high-profile merger, a promising late development project deemed not approvable, an unforeseen patent extension of a high-sale therapy, a major production or manufacturing setback, or any other similarly unpredictable event.
Kalorama Information's report goes into detail about current market share percentages among companies in the breast cancer, lung cancer, lymphoma, asthma and Alzheimer's segments and where the market share will be in 2022. Its report is available at: https://www.kaloramainformation.com/Potential-Pipeline-Disruptors-10848169/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
212 807 2262
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-report-finds-two-potential-market-disruptors-in-the-drug-pipeline-300462562.html
SOURCE Kalorama Information